The goal of the study is to characterize the relationship between portal vein thrombosis (PVT) and hepatic atrophy in patients without cirrhosis and the effect of various types of surgical shunts on liver regeneration and splenomegaly. Patients without cirrhosis with PVT suffer from presinusoidal portal hypertension, and often hepatic atrophy is a topic that has received little attention. We hypothesized that patients with PVT have decreased liver volumes, and shunts that preserve intrahepatic portal flow enhance liver regeneration. Sixty-four adult and pediatric patients with PVT who underwent surgical shunt placement between 1998 and 2011 were included in a retrospective study. Baseline liver volumes from adult patients were compared with standard liver volume (SLV) as well as a group of healthy controls undergoing evaluation for liver donation. Clinical assessment, liver function tests, and liver and spleen volumes from cross-sectional imaging were compared before and after surgery. A total of 40 patients received portal flow-preserving shunts (32 mesoportal and 8 selective splenorenal), whereas 24 received portal flow-diverting shunts (16 nonselective splenorenal and 8 mesocaval). Baseline adult liver volumes were 26% smaller than SLV (1248 versus 1624 cm 3 ; P 5 0.02) and 20% smaller than the control volumes (1248 versus 1552 cm 3 ; P 5 0.02). Baseline adult spleen volumes were larger compared with controls (1258 versus 229 cm 3 ; P < 0.001). Preserving shunts were associated with significant increase in liver volumes (886 versus 1131 cm 3 ; P 5 0.01), whereas diverting shunts were not. Diverting shunts significantly improved splenomegaly. In conclusion,
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Portal vein thrombosis (PVT) often develops in the setting of liver cirrhosis secondary to numerous factors including stagnation of portal flow and hyperestrogenemia. (1, 2) PVT has also been reported in patients without cirrhosis and is often associated with bowel inflammation, pancreatitis, hypercoagulable states, and following umbilical vein catheterization in the newborn. (1) (2) (3) Patients without cirrhosis with PVT are known to have severe portal hypertension and usually present with upper gastrointestinal (UGI) bleeding, hypersplenism, and potentially portal biliopathy, but typically they do not develop ascites or clinically significant encephalopathy. (4, 5) Liver histological and morphological changes, including liver atrophy, have been linked to PVT in the absence of chronic liver disease. (6, 7) It has long been known that portal blood is necessary to maintain adequate liver mass, initially demonstrated in Starzl's work leading to the "hepatotrophic hypothesis." (8) (9) (10) Hepatocellular apoptosis is thought to be a transient response to ischemia in acute PVT, whereas liver atrophy and nodular regenerative hyperplasia are the longterm sequelae. (11) However, the effect of PVT on liver and spleen Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSA, body surface area; INR, international normalized ratio; IQR, interquartile range; PDS, polydioxanone suture; PVT, portal vein thrombosis; SD, standard deviation; SLV, standard liver volume; UGI, upper gastrointestinal.
volumes in comparison to healthy controls has not been characterized.
Nonoperative management of PVT includes systemic anticoagulation and treatment of varices via systemic and local approaches. Patients often require multiple endoscopic interventions aiming at preventing as well as treating bleeding esophageal varices. (12) Successful endovascular thrombolysis of PVT was first reported by Bizollon et al. in 1991 and is limited to the acute setting. (13) Thrombosis of the portal vein precludes the use to transjugular intrahepatic portal systematic shunts for relief of the symptoms of portal hypertension. Therefore, upon exhaustion of optimal medical and endovascular management approaches to control disease progression, surgical intervention is often sought. Different types of surgical approaches aiming at decompression of the portal circulation have been adopted and modified over the years. (14) Nonselective shunts divert the entire portal flow toward the systemic circulation, bypassing the liver. Although these types of shunts immediately alleviate the symptoms of portal hypertension, they in fact potentiate the ischemic effect on the liver and put the patient at a high risk of developing low-grade hepatic encephalopathy. (15) Selective shunts, such as the distal splenorenal shunt, decrease portal pressure but preserve a portion of portal blood flow to the liver. (16, 17) In 1992, de Ville de Goyet et al. described a unique type of surgical shunt connecting the superior mesenteric vein to the umbilical portion of the left portal vein to relieve extrahepatic portal hypertension after partial liver transplant. (18) This mesoportal shunt leads to restoration of physiologic portal blood flow to the liver and guards against the longterm consequences of portosystemic shunting. (19) The patient's internal jugular vein is commonly used as an autograft for the mesoportal shunt with satisfactory outcomes. (20) The occasional insufficient length of the internal jugular vein among other technical reasons have led to variable modifications of the original technique using different types of autologous and synthetic grafts. (21) (22) (23) At our institution, all patients presenting with PVT in the absence of liver cirrhosis are evaluated for mesoportal shunt creation. Cross-sectional imaging is obtained as part of the evaluation process to assess the extent of portal vein occlusion and ensure patency of the left portal vein. In this study, we sought to confirm the relationship between PVT and liver atrophy. We further attempted to demonstrate the effect of the various types of surgical shunts on liver regeneration and splenomegaly.
Patients and Methods

PATIENTS AND INCLUSION CRITERIA
The present study was conducted after obtaining approval from the local institutional review board. All adult and pediatric patients diagnosed with PVT who received surgical intervention for the purpose of decompression of the portal circulation at our institution between 1998 and 2011 were included in a retrospective cohort. The electronic medical record built-in search engine was used to query each patient's chart for the keywords cirrhosis and fibrosis, and all patients with clinical, radiological, or histological evidence of liver cirrhosis were excluded from the study. During this period, the approach to diagnosis and management of patients with PVT had been consistent. Cross-sectional imaging was obtained on all patients with PVT to confirm the diagnoses, assess the clot burden, as well as to define vascular anatomy and alterations of liver and spleen volume and morphology. Imaging was used specifically to define the patency of the mesenteric and splenic veins and to determine the patency of the intrahepatic portal circulation. The decision to obtain computerized tomographic or magnetic resonance studies was based on clinician Abdulrhman S. Elnaggar wrote the institutional review board proposal, performed data analysis, and was the primary author for this manuscript. Adam D. Griesemer performed the data analysis and assisted in writing and editing the manuscript. Stuart Bentley-Hibbert performed volumetric analyses of livers and spleens. Robert S. Brown Jr, Mercedes Martinez, Steven J. Lobritto, and Tomoaki Kato participated in patient care and reviewed and edited the manuscript. Jean C. Emond performed study design, assisted in data analysis, and reviewed and edited the manuscript.
preference. All patients underwent hypercoagulability workup and the use, choice, and duration of anticoagulation was at the discretion of the clinicians. We used a validated formula (18.51 [kg body weight] 1191.80) to predict liver volumes based on body weight and compared these standard liver volumes (SLVs) with the measured liver volumes in patients with PVT. (24) Moreover, a group of healthy adults who received cross-sectional imaging as part of the evaluation process for liver donation at our institution was used as a control for liver and spleen volumes in the healthy population. The purpose of using this control group was to compare their liver and spleen volumes with the adult patients with PVT prior to surgical intervention.
SURGICAL PROCEDURES
Each patient received 1 of 3 types of surgical interventions (shunts) for decompression of the portal circulation and alleviation of portal hypertension. These interventions were reconstructive mesoportal shunts (Rex), selective distal splenorenal shunts, and nonselective shunts including side-to-side splenorenal or mesocaval shunts. For the sake of the study, these types were categorized into 2 groups: the portal flow-preserving shunts, including mesoportal and selective splenorenal shunts; and the portal flow-diverting shunts, including nonselective splenorenal and mesocaval shunts. The extent of the portal vein thrombus beyond the splenomesenteric confluence was the major precluding factor to performing the mesoportal shunt in addition to the patency of left portal vein, which was assessed on preoperative imaging as well as by intraoperative exploration. The internal jugular vein was harvested and used as a conduit between the splenomesenteric confluence and the left intrahepatic portal vein in all patients who received mesoportal shunts (Fig. 1) . Nonselective splenorenal shunts were performed in a side-to-side fashion or by anastomosing the distal end of the adrenal vein to the side of the splenic vein. 
CLINICAL DATA COLLECTION
All data collection activities occurred retrospectively including basic demographics, clinical assessment, standard laboratory variables including markers of liver and spleen function, as well as cross-sectional imaging. Several time points were chosen for data collection starting with the preoperative assessment and including multiple postsurgical follow-up points. Intraoperative and postoperative surgical outcome data were also included in the database. Data collection for the control group was limited to basic demographics and cross-sectional imaging variables. Follow-up was ascertained between 5 and 18 years.
IMAGING AND SEGMENTATION ALGORITHMS
Liver and spleen volumes were calculated from crosssectional imaging obtained prior to surgery and following surgical intervention for patients and at a single time point for the healthy controls. An in-house segmentation algorithm was applied to semiautomatically delineate liver and spleen contours on each scan. The computer-generated contours were visually inspected and modified, if needed, by a group of radiologists who were blinded to all clinical information. Volumes of livers and spleens were then calculated based on the final contour results.
STATISTICAL METHODS
At baseline, cross-sectional liver volumes were compared with SLVs for each patient using the pairedsample t test. Liver and spleen volumes from the control group were also compared with the adult patients using the independent-sample t test. Liver and spleen volumes prior to surgical intervention were then compared with follow-up volumes across the 2 shunt categories using the paired-sample t test. Baseline laboratory values that reflect liver and spleen function were also compared with follow-up values across the 2 shunt categories using the paired-sample t test.
Results
DESCRIPTION OF PATIENT POPULATION
A total of 64 patients were included in the final analysis. Of all patients included, 55% were males, and 52% were adults at the time of surgical intervention (Table 1) . A total of 40 patients underwent portal flow-preserving shunts, whereas 24 patients underwent portal flow-diverting shunts. Of the 40 patients who received the portal flow-preserving shunt, 32 received mesoportal shunts, and 8 received selective splenorenal shunts. Of the 24 patients who received the portal flow-diverting shunt, 16 received nonselective splenorenal shunts, and 8 received mesocaval shunts. Sixty percent of patients in the portal flow-preserving group were children compared with 30% in the portal flowdiverting group (P 5 0.02). Fifty-six percent of patients had presurgical and at least 1 postsurgical cross-sectional imaging available allowing for comparison at the time of data analysis. The median number of months from the date of surgical intervention to follow-up imaging was 5.73 in the portal flow-preserving shunt group and 11.16 in the portal flow-diverting shunt group (P 5 0.21). A control group of 29 healthy controls were retrospectively included in the analysis and cross-sectional liver and spleen volumes from this group were compared with the adult patients with PVT at baseline.
LIVER AND SPLEEN VOLUMES
At baseline, cross-sectional liver volumes were significantly smaller when compared with the SLVs for the entire patient cohort (P 5 0.01; Table 2 ). Moreover, on comparing cross-sectional liver volumes with SLVs in the adult and pediatric patients separately, the same pattern was noted (Table 2) . Subsequently, when comparing the adult patients (n 5 33) at baseline with the healthy donor controls (n 5 29), there was no significant difference in age, height, weight, and body surface area (BSA) between both groups (Table 3) . There were more females in the healthy control group (P 5 0.01). Cross-sectional liver volumes obtained from adult patients were significantly smaller compared with the control group (P 5 0.02), and spleen volumes were found to be significantly larger (P < 0.001; Table 3 ; Fig. 2 ). Cross-sectional liver and spleen volumes at baseline were then compared with postsurgical follow-up volumes in both the portal flow-preserving and diverting shunt groups. Follow-up liver volumes were significantly larger compared with baseline only in patients who received portal flow-preserving shunts (P 5 0.01; Table 4 ). No significant spleen volume reduction was noted in this group. However, in patients who received portal flow-diverting shunts, a significant spleen volume reduction was achieved (P 5 0.01) with no significant change in liver volumes.
A subgroup analysis was performed, and only 11 adult and pediatric patients who underwent mesoportal shunts had preoperative and postoperative crosssectional imaging available for comparison. In this group, there was a significant increase in liver volumes (838 6 487 versus 1077 6 608 cm 3 ; P 5 0.01) and no significant change in spleen volumes (863 6 931 versus 823 6 1102 cm 3 ; P 5 0.63). Upon excluding the pediatric patients, only 4 adult patients were available for comparison and they had an insignificant increase in liver volumes (1281 6 463 versus 1581 6 503 cm 3 ; P 5 0.05) and no significant change in spleen volumes (1573 6 1399 versus 1771 6 1622 cm 3 ; P 5 0.31).
Standard laboratory markers of liver function and portal hypertension at baseline were compared with postsurgical follow-up in both groups. Although there was no significant reduction in spleen size in patients received preserving shunts, follow-up platelet counts were significantly higher than baseline in this group (P 5 0.01; Table 5 ). Lastly, follow-up international normalized ratio (INR) was found to be significantly higher in the diverting shunt group (P 5 0.04).
Discussion
The present study is the first report to our knowledge to establish the relationship between PVT and liver atrophy in patients without cirrhosis through the NOTE: Data are given as n (%) or mean 6 SD.
FIG. 2.
Baseline adult liver and spleen volumes. Adult liver and spleen volumes prior to surgical intervention measured in cubic centimeters. Liver volumes shown in the first bar are significantly smaller compared with SLVs calculated for the same patients, healthy controls and SLVs calculated for the controls. comparison of liver volume from a series of patients with PVT and a group of healthy controls. Female sex is thought to be associated with smaller liver volumes compared with males with the same body weight. (25, 26) Even though the control group contained more female patients, it remained evident that patients with PVT had suffered a significant liver atrophy compared with the control group. Although Glatard et al. suggested the presence of liver atrophy in patients with PVT, estimation of liver atrophy was subjective and based on the radiologist's expert opinion, not quantitative measurements. (7) Liver atrophy in this patient population, especially in children, may have a significant effect on cognitive function and somatic growth. (27) We have also shown that surgical shunts that restore and/or preserve collateral intrahepatic portal flow lead to significant liver regeneration demonstrated by increase in liver volume. The portal flow-preserving shunt, however, failed to significantly improve splenomegaly and alleviate hypersplenism in our cohort. On the other hand, the portal flow-diverting shunt resulted in significant reduction in spleen volume with no significant effect on liver regeneration. Although others have demonstrated that mesoportal shunts result in increased hepatic volumes, (28) our study is the first to compare the differential effect of shunt type on hepatic volume augmentation.
In a separate study, we attempted to define the "normal" spleen volume by studying a cohort of living donors in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study. (29) In the setting of liver disorders, platelet count is often used, among other markers, as an indicator for hypersplenism. Although significant spleen size reduction was achieved only following creation of the portal flowdiverting shunts, there was no corresponding increase in platelet count. This suggests that in patients without cirrhosis but with PVT, there is a second mediator of thrombocytopenia in addition to splenic sequestration of platelets. Interestingly, we recorded a significant increase in platelet count in patients who received the portal flow-preserving shunts. Lautz et al. reported a similar finding in children who received a mesoportal shunt for extrahepatic PVT. (30) They also demonstrated that the INR significantly improved following mesoportal shunt. However, our data failed to show the same observation. The improvement in platelet count following portal flow-preserving shunts could be due to an increase in the synthesis of thrombopoietin by the regenerated liver, which plays an essential role in thrombopoiesis. (31) This study carries the limitations of the retrospective, nonrandomized design. The formula used to predict liver volumes is not validated in the pediatric population and given the large number of pediatric patients in this study, it may have an impact on the discrepancy between estimated and calculated liver volumes. In addition, some of the postoperative liver volume increase could be attributed to the physiologic growth of these children despite the evidence of somatic growth retardation in children with PVT. (27) However, pediatric physiologic growth is less likely to be a significant confounder given the relative short time between surgery and postsurgical imaging of 5.73 months. In the subgroup analysis, our study was underpowered to show a significant increase in liver volumes in adult patients who underwent mesoportal shunts. Moreover, due to the retrospective nature of the study, excluding patients with cirrhosis was not always based on liver biopsies or hepatic vein gradients.
Traditionally, the surgical management of patients without cirrhosis but with PVT has been focused mainly on the prevention of UGI bleeding. All surgical shunts, including mesoportal shunt, have been shown to have excellent results for preventing UGI bleeding. (14, 28, 32) Since the introduction of the mesoportal shunt, there has been an increasing body of evidence showing growth and cognitive advantages to this technique. (27, (33) (34) (35) (36) The current surgical management of patients without cirrhosis but with PVT should be directed toward restoration and/or preservation of hepatopetal portal flow via mesoportal shunt whenever feasible. Further prospective work evaluating hepatic regeneration markers and neurocognitive function combined with morphologic assessment of liver growth will be needed. 
